Myrtelle

Myrtelle is a startup based in the United States. Brouky classifies it under Healthcare & Life Sciences.

Myrtelle is developing gene therapies that target oligodendrocytes to treat myelin disorders and other neurodegenerative diseases. Its lead candidate, rAAV-Olig001-ASPA, is a proprietary AAV gene therapy for Canavan's disease and has been granted FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations.